Antiplatelet Therapy in a Patient with Coronary Artery Disease and Myelodysplastic Syndrome with Thrombocytopenia
To date, there are no sufficient data to make firm recommendations on the treatment of patients with severe thrombocytopenia who require antiplatelet therapy after experiencing acute coronary syndrome. Therefore, we think that it is important to communicate the experience with individual cases. We r...
Main Authors: | Francisco José Fernández-Fernández, Eugenia Ameneiros-Lago, Cintia Tuñas-Gesto, Inmaculada Gómez-Buela |
---|---|
Format: | Article |
Language: | English |
Published: |
Karolinum Press
2017-10-01
|
Series: | Acta Medica |
Subjects: | |
Online Access: | https://actamedica.lfhk.cuni.cz/60/2/0082/ |
Similar Items
-
Can antiplatelet therapy after drug eluting stent become a problem?
by: Michele Romano
Published: (2009-03-01) -
Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma
by: Surya Chaturvedula, et al.
Published: (2018-04-01) -
Best duration of dual antiplatelet therapy after drug-eluting stent implantation: an updated network meta-analysis of randomized controlled trials
by: Mahmoud Barbarawi, et al.
Published: (2019-01-01) -
What is the Optimal Duration of Dual Antiplatelet Therapy After Stenting?
by: Udaya S. Tantry, PhD, et al.
Published: (2016-05-01) -
Optimizing the Duration of Dual Antiplatelet Therapy After Implantation of Drug-eluting Coronary Stents
by: Ying Shen, et al.
Published: (2015-01-01)